At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
HAVbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Assessment of Humacyte's Human Acellular Vessel in Patients Needing Vascular Access for Dialysis
In Brief
A Phase 2 clinical trial evaluating HAV for Renal Failure and 3 related conditions. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
This is a Phase 2, prospective, multicenter, open-label, single-arm study of the Human Acellular Vessel (HAV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Failure, End Stage Renal Disease, Vascular Access, Hemodialysis
CountriesPoland
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionMay 2021
Study CompletionMar 2022
TodayJul 2026
First PostedOct 22, 2019
Enrollment StartNov 12, 2019
Primary CompletionMay 15, 2021
Study CompletionMar 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.7 years ago
Interventions
HAVbiological
Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.